Citrullinated Peptide Adsorbent Columns for Selective Antibody Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing blood treatment methods face challenges in effectively reducing undesired blood group specific antibodies and autoimmune antibodies, particularly in conditions like myasthenia gravis and rheumatoid arthritis, due to contamination risks and inefficiencies in adsorbent integrity and specificity.
Innovation Solution
A kit containing a column with a covalently bound adsorbent comprising linear and cyclic citrullinated peptides, housed in a sealed plastic bag for autoclaving, ensures sterility and maintains adsorbent integrity, allowing selective binding and reduction of target antibodies in blood or plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing blood treatment methods are used to reduce undesired antibodies, then antibody reduction is achieved, but contamination risks increase and adsorbent integrity is compromised
Solution Approach 1:
The adsorbent is pre-packaged in a sealed container before use, maintaining sterility and integrity until the moment of application. This preliminary preparation prevents contamination and preserves adsorbent functionality throughout storage and handling.
Solution Approach 2:
A sealed container acts as an intermediary barrier between the adsorbent and the external environment, preventing contamination while allowing controlled access during treatment. The container mediates between the need for sterility and the need for operational access.
2Productivity
If conventional adsorbents are used for blood treatment, then some antibody binding occurs, but binding specificity and efficiency are insufficient
Solution Approach 1:
The adsorbent surface is modified with specific citrullinated peptide sequences that provide localized binding sites with high specificity for target antibodies. Different regions of the adsorbent contain optimized peptide configurations for maximizing both binding efficiency and specificity.
Solution Approach 2:
The adsorbent combines citrullinated linear and cyclic peptides with a porous matrix material to create a composite structure that enhances both binding capacity and specificity. The composite nature allows optimization of multiple properties simultaneously.
3Ease of operation
If adsorbent is exposed to blood components before use, then adsorbent becomes activated, but adsorbent functionality deteriorates due to premature binding
Solution Approach 1:
The adsorbent is prepared and sealed in advance in a sterile state, maintaining its binding capacity intact until needed. This preliminary preparation ensures the adsorbent is ready for immediate use without premature activation or degradation.
Solution Approach 2:
The adsorbent is extracted from its protective sealed container only at the moment of use, preventing exposure to blood components during storage and handling. This separation maintains adsorbent functionality until the critical moment of application.
4Adaptability or versatility
If multiple antibody types are targeted simultaneously, then comprehensive treatment is achieved, but device complexity increases
Solution Approach 1:
The adsorbent is designed with multiple citrullinated peptide sequences that can simultaneously bind different types of autoantibodies including anti-citrullinated protein antibodies and rheumatoid factor. This multi-functional design allows comprehensive treatment without requiring multiple separate columns.
Solution Approach 2:
Multiple antibody-targeting capabilities are merged into a single adsorbent formulation containing diverse citrullinated peptide sequences. This consolidation achieves comprehensive antibody reduction in one treatment pass rather than requiring sequential treatments with separate adsorbents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit provides reliable and efficient reduction of undesired antibodies, minimizing contamination risks and maintaining adsorbent functionality, enabling effective treatment of myasthenia gravis and rheumatoid arthritis by reducing antibody content in blood or plasma.
Implementation Method 1
an adsorbent comprising at least two types of covalently bound antigens having the ability to bind at least one component present in a blood flow or blood plasma flow passing through said adsorbent
Implementation Method 2
said at least two types of antigen comprises at least one linear peptide and at least one cyclic peptide... having the ability to bind at least one component present in a blood flow
Data Source
AI summary
An adsorbent comprising at least two types of covalently bound antigens having the ability to bind at least one component present in a blood flow or blood plasma flow passing through said adsorbent is disclosed, as well as a column containing said adsorbent, a kit containing said column in a sealed plastic bag, a method for the production of said kit, a method for reduction or elimination of undesired blood group specific antibodies or autoimmune antibodies in connection with autoimmune diseases, a method for treatment of myasthenia gravis, and a method for treatment of rheumatoid arthritis.